#USA #New York #Faruqi & Faruqi #Marex Group #NASDAQ MRX

Marex Group Investigation by Faruqi & Faruqi, LLP

On October 15, 2025, leading national securities law firm Faruqi & Faruqi, LLP announced that it is actively investigating potential claims on behalf of investors of Marex Group plc (NASDAQ: MRX). This investigation comes in light of serious allegations against Marex related to potential securities violations.

Background of the Investigation

Faruqi & Faruqi, represented by Securities Litigation Partner James (Josh) Wilson, is encouraging investors who purchased or acquired securities in Marex Group between May 16, 2024, and August 5, 2025, to discuss their circumstances. They can reach out to Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for further legal inquiry.

The firm is particularly reminding investors of the upcoming December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has already been filed against Marex. This timeline adds a layer of urgency for affected shareholders to come forward.

Allegations Against Marex Group

The heart of the investigation stems from allegations that Marex and its executives violated federal securities laws by making misleading statements and failing to disclose critical financial discrepancies. These allegations include:

• - The unauthorized sale of over-the-counter financial instruments to itself.
• - Inconsistencies in financial statements regarding intercompany loans and receivables between subsidiaries and related parties.
• - Resulting reliance issues on Marex’s financial statements.
• - Misleading positive statements regarding the Company’s operations and prospects.

The investigation gained traction following a report published on August 5, 2025, by NINGI Research, which criticized Marex for a prolonged accounting scheme utilizing off-balance-sheet entities, fictitious transactions, and incorrect disclosures designed to obscure significant financial losses. Key examples reported included:

• - A fabricated receivable amounting to $17 million.
• - Inflated profits from subsidiaries.
• - Concealment of approximately $1 billion in derivatives exposure through a Luxembourg-based fund.

Due to these revelations, Marex's stock experienced a notable decline, dropping 6.2% to close at $35.31 amid increased trading volume.

Role of the Lead Plaintiff

In securities class actions, the lead plaintiff is the investor deemed to have the largest financial stake in the case, typically serving as the main conduit for communicating on behalf of the class. Any member of the potential class can file a motion with the court to be designated as lead plaintiff, either on their own or through their chosen legal representation. Importantly, electing to be a lead plaintiff does not affect the ability to recover from the action; it merely provides an influential position within the proceedings.

Continued Invitation for Information

Faruqi & Faruqi emphasizes its commitment to potential claimants and invites anyone with information regarding Marex's practices to step forward. This includes whistleblowers, former employees, and shareholders who may possess insights that could prove beneficial to the ongoing investigation.

For additional details regarding the Marex Group class action investigation, individuals are encouraged to visit Faruqi & Faruqi's official website or call James (Josh) Wilson directly.

Conclusion

As the investigation unfolds, impacted investors are urged to take proactive steps. With a significant deadline approaching, engagement with legal experts like those at Faruqi & Faruqi could prove crucial in navigating the forthcoming legal landscape concerning Marex Group.